Skip to main content

Affymetrix's Q4 Revenues Slide 6.5 Percent as Profit Plummets 72 Percent

NEW YORK (GenomeWeb News) —Affymetrix today said fourth-quarter revenues decreased 6.5 percent as R&D spending remained flat and profit plummeted 72 percent.
 
Total receipts for the three months ended Dec. 31, 2006, decreased to $104.2 million from $111.4 million year over year.
 
Product and product-related revenue decreased 9.5 percent to $95 million; royalties and "other" revenue increased 115 percent to $6.6 million; and receipts from Perlegen slid 5.5 percent to $2.6 million.
 
R&D spending was flat at $19.6 million.
 
The company said profit declined to $8.7 million from $30.6 million in the year-ago period.
 
Affy said it had around $119 million in cash and equivalents and $118 million in short-term investments as of Dec. 31.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.